Get started
Author

Evangelos Fousteris

Observed names: E. Fousteris, EVANGELOS FOUSTERIS
ORCID: 0009-0001-0505-0395
Observed ORCID: 0009-0001-0505-0395
OpenAlex ID: A5005869758
Toll/Interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction
2011 · Evangelos Fousteris, Andreas Melidonis, et al. · Cardiovascular Diabetology · 71
PDF
Head-to-head comparison of 2 inflammatory biomarkers for the long-term prediction of left ventricular diastolic dysfunction in type 2 diabetes patients: Soluble ST2 versus hs-CRP
2014 · Evangelos Fousteris, Anastasios Theodosis-Georgilas, et al. · International Journal of Cardiology · 10
Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity, but without diabetes mellitus: a prospective observational study
2025 · Nikolaos Angelopoulos, Sarantis Livadas, et al. · Journal of Diabetes and its Complications · 9
Evaluation of IScore validity in a Greek cohort of patients with type 2 diabetes
2013 · Vasileios Dragoumanos, Konstantinos N Tzirogiannis, et al. · BMC Neurology · 8
PDF
A real-world study of tirzepatide for weight loss in adults without diabetes mellitus
2025 · Nikolaos Angelopoulos, Ioannis Androulakis, et al. · International Journal of Obesity · 7
Six‐Month Real‐World Effectiveness, Persistence and Safety of Low‐to‐Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study
2026 · Nikolaos Angelopoulos, Dimitra Zianni, et al. · Diabetes Obesity and Metabolism · 5
Circulating Beta-Defensin 2 Levels Correlate with Conventional Inflammatory Markers in Infection-Free Individuals with Overweight and Obesity: An Exploratory Study
2025 · Theocharis Koufakis, Dimitrios Kouroupis, et al. · Biomedicines · 5
PDF
The Impact of Continuous Subcutaneous Insulin Infusion Therapy on Efficacy and Safety in a Cohort of Type 1 Diabetes Patients: A 3-Year Prospective Study
2016 · Andreas Melidonis, Alexandros Kamaratos, et al. · Diabetes Technology & Therapeutics · 5
Stress cardiac magnetic resonance reveals myocardial perfusion impairment in asymptomatic diabetes mellitus type I, missed by the routine non-invasive evaluation
2013 · Sophie Mavrogeni, Konstantinos Bratis, et al. · International Journal of Cardiology · 5
Obesity in Type 1 Diabetes: Moving Beyond the “Lean” Disease Paradigm to Understand Risk, Complications, and Treatment
2026 · Anastasios Tentolouris, Theocharis Koufakis, et al. · Current Obesity Reports · 4
PDF
Diabetic ketoacidosis as first presentation of latent autoimmune diabetes in adults in a patient with hashitoxicosis as first presentation of Hashimoto’s thyroiditis: a case report
2022 · Maria Xenou, Ioannis Zoupas, et al. · Journal of Medical Case Reports · 4
PDF
Early changes in body composition with tirzepatide in adults with obesity: a real-world BIA study
2026 · Nikolaos Angelopoulos, Andreas Rizoulis, et al. · Nutrition · 3
Predictors of left ventricular diastolic dysfunction in type 2 diabetes patients: A 4-year prospective study
2016 · Evangelos Fousteris, Athanasia Papazafiropoulou, et al. · Hellenic Journal of Cardiology · 3
PDF
12-month weight-loss trajectories and predictors of response to tirzepatide under individualized dosing: A multicenter real-world study
2026 · Nikolaos Angelopoulos, Evangelos Fousteris, et al. · Obesity Pillars
Short-Term Effects of Low-Dose Tirzepatide on Lipid Profile in Non-Diabetic Adults: A Prospective Observational Study
2026 · Rodis Paparodis, Nikolaos Angelopoulos, et al. · Journal of clinical lipidology
Author response for "Six-Month Real-World Effectiveness, Persistence, and Safety of Low-to-Moderate Dose Tirzepatide in Adults with Obesity: A Multicenter Observational Study"
2026 · Nikolaos Angelopoulos, Dimitra Zianni, et al. · Publons reviews and discussion
Author response for "Six-Month Real-World Effectiveness, Persistence, and Safety of Low-to-Moderate Dose Tirzepatide in Adults with Obesity: A Multicenter Observational Study"
2026 · Nikolaos Angelopoulos, Dimitra Zianni, et al. · Publons reviews and discussion
Elevated body mass index amplifies inflammation-linked diastolic dysfunction independent of diabetes: a two-year prospective study
2026 · Evangelos Fousteris, Konstantinos Arvanitakis, et al. · Acta Diabetologica
88-LB: Kidney and Metabolic Benefits by Adding GLP-1 Agonists and/or SGLT2 Inhibitors on Metformin in Obese Type 2 Diabetes (T2DM) Patients: 24-Month Real-World Data from Both Urban and Rural Clinics
2021 · IOANNIS ZOUPAS, ATHANASIA PAPAZAFIROPOULOU, et al. · Diabetes
120-LB: The Metabolic Effects of Initiation Pitavastatin vs. Rosuvastatin: Twelve Months Real-World Data on Hyperlipidemic Patients with and without Diabetes (DM)
2021 · DIMITRIOS LYGNOS, ATHANASIA PAPAZAFIROPOULOU, et al. · Diabetes
Latest data on obesity
2017 · Evangelos Fousteris · DOAJ (DOAJ: Directory of Open Access Journals)
Stress cardiac magnetic resonance imaging reveals hypoperfusion in asymptomatic type 1 diabetes patients, missed by the routine non-invasive evaluation
2013 · Αndreas Μelidonis, Konstantinos Bratis, et al. · Data Archiving and Networked Services (DANS)
Poster session Friday 7 December - PM: Effect of systemic illnesses on the heart
2012 · L. Iliuta, K. Uno, et al. · European Heart Journal - Cardiovascular Imaging
Type 2 Diabetes Is Connected With Higher Soluble St2 Levels, Even Higher When Left Ventricular Diastolic Dysfunction Is Present
2011 · Evangelos Fousteris, George Panoutsopoulos, et al. · European Journal of Internal Medicine
Association of Antidiabetic Medication to Long Term Prognosis After an Ischemic Stroke
2011 · Vassilios Dragoumanos, Evangelos Fousteris, et al. · European Journal of Internal Medicine
Works count: 26
Citation count: 139
H-index: 5
I10-index: 2
Year
Topic
Type